MCM
HRMY icon

MAI Capital Management’s Harmony Biosciences HRMY Stock Holding History

MAI Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,040
Closed -$29.1K – 3253
2026
Q1 		$29.1K Buy
1,040
+1,013
+3,752% +$33.2K ﹤0.01% 2573
2025
Q4 		$1.01K Buy
+27
New +$888 ﹤0.01% 3628

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's HRMY Position: Q2 2026 in Review

MAI Capital Management sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 1,040 shares — an estimated $29.1K sold.

MAI Capital Management first reported a position in HRMY in Q4 2025 and held it in 2 quarters. The position peaked at $29.1K in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • MAI Capital Management reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,040 Harmony Biosciences shares in Q2 2026, an estimated $29.1K.
  • MAI Capital Management first reported a position in Harmony Biosciences in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Harmony Biosciences position peaked at $29.1K in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.